Teva gets approval in China for Huntington's disease treatment
Teva’s CEO Kare Schultz said the drug would be priced somewhat lower in China than in the United States.
A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem(photo credit: REUTERS/BAZ RATNER)ByREUTERS
